Compare ELTK & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELTK | IXHL |
|---|---|---|
| Founded | 1970 | 2001 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.3M | 45.0M |
| IPO Year | 1998 | 2024 |
| Metric | ELTK | IXHL |
|---|---|---|
| Price | $8.31 | $3.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.7K | ★ 475.4K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $16.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.73 | $0.11 |
| 52 Week High | $12.19 | $6.39 |
| Indicator | ELTK | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 63.34 |
| Support Level | $7.79 | $0.34 |
| Resistance Level | $9.34 | $5.17 |
| Average True Range (ATR) | 0.37 | 0.30 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 54.89 | 93.16 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.